Common GLP-1 mistakes: what the science says vs. TikTok
Quick answer
GLP-1 receptor agonists like semaglutide and tirzepatide produce significant weight loss but are associated with lean body mass reduction, a concern that protein optimization and resistance training can help mitigate based on current evidence. The three lifestyle recommendations in this video, appetite awareness, adequate protein intake, and exercise, are consistent with general clinical guidance for patients on GLP-1 therapy, though individual response to appetite suppression varies considerably. Patients should discuss specific protein targets and exercise programming with their prescribing clinician rather than relying on general social media advice.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @realdrbae actually say?
Dr. Jonathan Kaplan, who identifies himself as the founder of a GLP-1 telehealth platform, laid out three mistakes he says people make when starting a GLP-1: overeating past fullness cues, skipping enough protein, and not exercising. He noted that lean body mass loss "can happen with any type of weight loss" and is not specific to GLP-1s. The video ends with a call to visit his platform.
The framing is practical and the claims are mostly in the right ballpark, but a few things deserve a closer look. The advice on protein and exercise is directionally correct. The overeating point is a bit murkier in practice. And the commercial framing is worth keeping in mind when evaluating who is giving you medical advice on TikTok.
Does the science back this up?
Largely yes, with some important nuance. The three pillars he names, appetite management, protein intake, and resistance exercise, are supported by clinical evidence in the context of GLP-1-assisted weight loss. But the science is more complicated than a 60-second video can capture.
On lean body mass: a 2023 trial by Wilding and colleagues published in Diabetes Care found that semaglutide users lost a meaningful proportion of lean mass alongside fat mass, consistent with what happens in other calorie-deficit contexts. So Kaplan is right that this is not unique to GLP-1s. A 2022 study by Cava et al. in Nutrients confirmed that higher protein intake during caloric restriction helps preserve lean mass, though optimal targets vary by individual. On exercise, a 2021 meta-analysis by Lopez et al. in Obesity Reviews found that resistance training combined with dietary intervention significantly reduced muscle loss during weight loss programs, which supports the exercise recommendation here.
What did they get wrong (or right)?
Kaplan gets the big picture right, and that matters. A lot of GLP-1 content on TikTok ignores muscle loss entirely or treats the drugs as a passive solution. He does not do that here.
Where it gets slippery is the overeating framing. He says fullness "might creep up on you fast" and warns against eating past it. That is accurate for some patients. But GLP-1s work partly by slowing gastric emptying and suppressing appetite signals, and the experience is not uniform. Some patients on lower doses barely notice appetite suppression. Presenting this as a top-three mistake implies it is predictable and universal, which is oversimplified. The advice to "take those fullness cues to heart" is reasonable, but it is not a mistake everyone makes or even can make, because not everyone feels those cues strongly at first.
His comment that "muscle mass burns more calories than fat mass" is accurate. Research from Zurlo et al. published in the American Journal of Physiology confirms that skeletal muscle has higher resting metabolic activity than fat tissue, though the difference per pound is smaller than fitness culture often claims.
What should you actually know?
If you are starting a GLP-1, protein and resistance exercise are genuinely worth prioritizing, and the evidence for both is real. Aim for adequate protein, and understand that specific targets should come from your prescribing clinician, not a TikTok comment section. Resistance training two to three times per week is a reasonable starting point supported by the literature on preserving lean mass during weight loss.
Nausea and GI side effects from overeating on a GLP-1 are real and reported frequently in clinical trials of semaglutide and tirzepatide. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found nausea affected over 30 percent of tirzepatide users, often linked to eating habits. Kaplan's point about listening to fullness cues is a reasonable harm-reduction message even if the framing is a little too neat.
One more thing: the creator is selling a service. That does not make his claims wrong, but it does mean his incentive is to simplify and reassure, not to walk through edge cases. Your actual clinical decisions about GLP-1 use, dosing, diet, and exercise should involve a licensed provider who knows your full history.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Common GLP-1 mistakes: what the science says vs. TikTok, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Common GLP-1 mistakes: what the science says vs. TikTok is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonists like semaglutide and tirzepatide produce significant weight loss but are associated with lean body mass reduction, a concern that protein optimization and resistance training can help mitigate based on current evidence.
FormBlends verdict
GLP-1 receptor agonists like semaglutide and tirzepatide produce significant weight loss but are associated with lean body mass reduction, a concern that protein optimization and resistance training can help mitigate based on current evidence. The three lifestyle recommendations in this video, appetite awareness, adequate protein intake, and exercise, are consistent with general clinical guidance for patients on GLP-1 therapy, though individual response to appetite suppression varies considerably. Patients should discuss specific protein targets and exercise programming with their prescribing clinician rather than relying on general social media advice.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide and tirzepatide produce significant weight loss but are associated with lean body mass reduction, a concern that protein optimization and resistance training can help mitigate based on current evidence. The three lifestyle recommendations in this video, appetite awareness, adequate protein intake, and exercise, are consistent with general clinical guidance for patients on GLP-1 therapy, though individual response to appetite suppression varies considerably. Patients should discuss specific protein targets and exercise programming with their prescribing clinician rather than relying on general social media advice.
- GI side effects including nausea affected over 30 percent of tirzepatide users in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), often linked to eating past fullness, supporting the appetite-awareness advice.
- Lean body mass loss during GLP-1 therapy is real but not unique to these drugs. It follows the same pattern seen in other calorie-deficit interventions, per Wilding et al. (2023, Diabetes Care).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GI side effects including nausea affected over 30 percent of tirzepatide users in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), often linked to eating past fullness, supporting the appetite-awareness advice.
- Lean body mass loss during GLP-1 therapy is real but not unique to these drugs. It follows the same pattern seen in other calorie-deficit interventions, per Wilding et al. (2023, Diabetes Care).
- Higher protein intake during caloric restriction is associated with better lean mass preservation. Cava et al. (2022, Nutrients) supports this, though individual protein targets should be set with a clinician.
- Resistance training combined with dietary intervention significantly reduces muscle loss during weight loss, per Lopez et al. (2021, Obesity Reviews). Adding a weight training routine is evidence-backed, not just gym culture advice.
- Skeletal muscle does have higher resting metabolic activity than fat tissue (Zurlo et al., American Journal of Physiology), but the calorie-burning difference per pound is smaller than often cited in fitness content.
- Appetite suppression on GLP-1s is not uniform. Some patients on lower starting doses feel little appetite change, so presenting overeating as a universal top mistake can set misleading expectations.
- The creator has a financial interest in his platform. His advice may be directionally sound, but clinical decisions about GLP-1 therapy require a licensed provider who knows your individual health history.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Jonathan Kaplan · TikTok creator
51.8K views on this video
Common mistakes people make on GLP-1s:
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Jonathan Kaplan, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.